| Keywords: |
mitogen activated protein kinase; protein kinase b; cancer chemotherapy; overall survival; thalidomide; clinical trial; drug activity; sorafenib; bevacizumab; cisplatin; cytotoxic agent; doxorubicin; erlotinib; fluorouracil; interferon; placebo; liver cell carcinoma; systemic therapy; antineoplastic agents; carcinoma, hepatocellular; clinical trials as topic; liver neoplasms; conference paper; drug targeting; capecitabine; gemcitabine; chemotherapy; dendritic cell; epidermal growth factor receptor; antineoplastic activity; cancer cell culture; drug resistance; cetuximab; phosphatidylinositol 3 kinase; transcription factors; panitumumab; drug delivery systems; clinical study; enzyme phosphorylation; immune response; immunotherapy; enzyme inhibitors; epigenetics; epigenesis, genetic; mammalian target of rapamycin; 1-phosphatidylinositol 3-kinase; comorbidity; gefitinib; protein farnesyltransferase inhibitor; tamoxifen; biologic therapy; dna topoisomerase (atp hydrolysing); oxaliplatin; mitogen-activated protein kinases; growth factor; clinical trials; correlational study; carcinogenic activity; growth inhibitors; hepatoma; chemoresistance; nolatrexed; hepatocellular; liver carcinogenesis; oncogene protein v-akt
|
